Bachelor of Science

L.E.K. Consulting Announces 11 New Global Partner Promotions

Retrieved on: 
Tuesday, January 9, 2024
Master of Engineering, ChromeOS, Stanford University, Biochemistry, School, Wellesley College, Imperial College London, London Business School, Master of Research, Tuck School of Business, Emlyon Business School, Health care, Mathematics, Commerce, Bell, Tuchman, University, Business, Consumer, Hydrogen, Digital, Babson College, Global education, Environment, Dartmouth College, Recycling, MBA, Bachelor of Science, Medtech, King's College London, Doctor of Philosophy, Pharma, St. Stephen's College, Master of Science, Mechanical engineering, L.E.K. Consulting, Construction, Organization, College, Queen's University, Education, Nataraja, Timm, Management

Consulting has elected 11 new partners.

Key Points: 
  • Consulting has elected 11 new partners.
  • The promotions recognize the significant expertise and insights that these leaders bring to bear for clients across multiple industry sectors and geographies who are facing critical decisions.
  • "We are pleased to announce the newest partner appointments at L.E.K.
  • With gratitude and pride, we congratulate them on this accomplishment and look forward to their continued impact and contributions to both our clients and our firm," said Clay Heskett, Global Manager Partner at L.E.K.

Aventi Group Announces Dean Nadorozny as VP Operations and Ajay Sharma as VP Finance

Retrieved on: 
Tuesday, January 9, 2024
Green, SAN, Everest University, Software as a service, Business, Metropolitan University, Ajay Sharma, Hockey, CPA, Alida (software company), MBA, CMA, Bachelor of Science, Behavioral neuroscience, Dean Foods, Marketing, Financial management, Toronto Metropolitan University, Growth, Management

The company warmly welcomes Dean Nadorozny as the new VP Operations and Ajay Sharma as VP Finance, marking a significant enhancement in its leadership dynamics.

Key Points: 
  • The company warmly welcomes Dean Nadorozny as the new VP Operations and Ajay Sharma as VP Finance, marking a significant enhancement in its leadership dynamics.
  • Of Dean's hire, Jeff Thompson, President and Co-Founder of Aventi Group, says, "We're thrilled to have Dean Nadorozny join the Aventi Group executive leadership team.
  • When asked about the addition of Ajay to the team, Sridhar Ramanathan, COO and Co-Founder of Aventi Group, says, "We are delighted to welcome Ajay Sharma as Vice President of Finance at Aventi Group.
  • Overall, the appointments of Dean Nadorozny and Ajay Sharma to Aventi Group's Executive Leadership Team are set to significantly bolster our operational and financial strategies.

YS Biopharma Announces Changes to its Board Committees

Retrieved on: 
Monday, January 8, 2024
Bachelor of Science, Accounting, Business, Audit committee, Vaccine, Guangdong Pharmaceutical University, YS, MBA, Cancer, Head, University, David G. Booth, Entrepreneurship, Compensated emancipation, Infection, Tea

GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect.

Key Points: 
  • GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company's Board of Directors (the "Board") has approved Ms. Rui Yu as the new Chairperson of its Audit Committee, as a member of its Compensation Committee, and as a member of the Nominating and Corporate Governance Committee on January 7, 2024 (Beijing Time), with immediate effect.
  • Ms. Yu currently serves as a partner at Oceanpine Capital, a position she has held since 2021.
  • Prior to that, she served as a managing director at China Renaissance Group and vice president and head of China healthcare research at Gerson Lehman Group.
  • Accordingly, the membership of each Board Committee will be as follows:
    Rui Yu (Chairperson), Viren Mehta, and Shaojing Tong
    Viren Mehta (Chairperson), Ajit Shetty, Shaojing Tong, and Rui Yu
    Ajit Shetty (Chairperson), Viren Mehta, Rui Yu, and Yi Zhang

Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer

Retrieved on: 
Friday, January 5, 2024
Liver, Bachelor of Science, Biotechnology, Anticalin, Foghorn, Research, University, S.A.C. Capital Advisors, Therapy, CIBC World Markets, Patient, Management

CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer, effective January 17, 2024.
  • A seasoned financial executive with over twenty years’ experience in the biotechnology industry, Dr. Reine will be responsible for the company’s financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company.
  • “I am delighted to welcome Allan to Prime Medicine.
  • He brings tremendous financial, operational and leadership experience in the life sciences space, as well as a proven track record developing and implementing multi-pronged strategies to finance a diverse pipeline and broad platform,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.

The American Diabetes Association Welcomes 2024 Principal Officers and Members to the National Board of Directors

Retrieved on: 
Wednesday, January 3, 2024
UCLA, Medicine, University, Pennsylvania State University, Bajaj, Public, Harvard University, Medicaid, Informatics, Johns Hopkins, Metabolism, Economics, Treatment, Medical Center, Luke the Evangelist, Conditional sentence, MBA, Harvard Business School, Urbański, Oregon State University, Doctor of Pharmacy, Anderson School of Management, Moda, Black, Medication, Baylor University, Bachelor of Science, Integrated delivery system, Division, Oklahoma State University–Stillwater, Kalyani, Education, Lee Ritenour, Medicare, Washington State University, Pharmacist, Committee on Finance, Cherokee Nation, Bon Secours Health System, Joslin Diabetes Center, Adventure, Management

ARLINGTON, Va., Jan. 3, 2024 /PRNewswire/ -- The American Diabetes Association® (ADA) welcomes the 2024 principal officers and board of directors.

Key Points: 
  • ARLINGTON, Va., Jan. 3, 2024 /PRNewswire/ -- The American Diabetes Association® (ADA) welcomes the 2024 principal officers and board of directors.
  • "We are so excited to announce our 2024 board of directors," said Charles "Chuck" Henderson, the ADA's chief executive officer.
  • We also want to thank our outgoing board members, Otis W. Kirksey, PharmD, RPh, CDCES, BC-ADM and Marshall Case.
  • We are very appreciative of their hard work, dedication, and commitment to fighting for all people affected by diabetes."

LeddarTech Appoints Oren Dayan as Vice-President of Product Line Management and Business Development

Retrieved on: 
Wednesday, January 3, 2024
Software engineering, Computer science, Mobileye, Business, Research, Industrial organization, Original equipment manufacturer, ADAS, Business development, Growth, Bachelor of Science, Management

As Vice-President of Product Line Management and Business Development, Mr. Dayan will be instrumental in executing the company's automotive software roadmap and the business development objectives of LeddarTech.

Key Points: 
  • As Vice-President of Product Line Management and Business Development, Mr. Dayan will be instrumental in executing the company's automotive software roadmap and the business development objectives of LeddarTech.
  • Before joining LeddarTech, Oren served as Vice-President of Business and Programs at automotive technology company Tri-Eye, where he was successful in strategic product and business development, leading to significant growth.
  • "I am honored and enthusiastic to take on the Vice-President of Product Line Management and Business Development role at LeddarTech," Mr. Dayan stated.
  • "I am delighted to welcome Mr. Dayan as our newly appointed Vice-President of Product Line Management and Business Development," said Mr. Antonio Polo, Sr.

LeddarTech Appoints Oren Dayan as Vice-President of Product Line Management and Business Development

Retrieved on: 
Wednesday, January 3, 2024
Software engineering, Computer science, Mobileye, Business, Research, Industrial organization, Original equipment manufacturer, ADAS, Business development, Growth, Bachelor of Science, Management

As Vice-President of Product Line Management and Business Development, Mr. Dayan will be instrumental in executing the company's automotive software roadmap and the business development objectives of LeddarTech.

Key Points: 
  • As Vice-President of Product Line Management and Business Development, Mr. Dayan will be instrumental in executing the company's automotive software roadmap and the business development objectives of LeddarTech.
  • Before joining LeddarTech, Oren served as Vice-President of Business and Programs at automotive technology company Tri-Eye, where he was successful in strategic product and business development, leading to significant growth.
  • "I am honored and enthusiastic to take on the Vice-President of Product Line Management and Business Development role at LeddarTech," Mr. Dayan stated.
  • "I am delighted to welcome Mr. Dayan as our newly appointed Vice-President of Product Line Management and Business Development," said Mr. Antonio Polo, Sr.

Heliostar Metals Adds Experienced Mine Builder as COO

Retrieved on: 
Tuesday, December 5, 2023
Metallurgy, Capstone, TSX Venture Exchange, Acquisition, Gold, Ana Paula, University, Moses Austin, Option, Safety, Bachelor of Science, Senior

Mr Bush is a proven mine builder with a strong track record of mine development, project integration and operations.

Key Points: 
  • Mr Bush is a proven mine builder with a strong track record of mine development, project integration and operations.
  • Previously, Mr. Bush was the COO of Capstone Mining Corporation for eight years.
  • Prior to these roles, Mr. Bush led the development and commissioning of the Dolores mine in Chihuahua, Mexico as COO of Minefinders Corporation.
  • Commenting on this appointment, Heliostar Metals CEO Charles Funk said, "Attracting a mine builder with the wealth and depth of experience as Gregg is a significant step forward for Heliostar.

MAG Announces the Appointment of Tom Peregoodoff to the Board of Directors as Part of Planned Board Succession

Retrieved on: 
Thursday, December 21, 2023
MAG, Sale, Mining, Bachelor of Science, Chairperson, BHP, Annual general meeting, TSX, Management

VANCOUVER, British Columbia, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG” or “MAG Silver”) is pleased to announce the appointment of Tom Peregoodoff to MAG’s Board of Directors effective January 1, 2024.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG” or “MAG Silver”) is pleased to announce the appointment of Tom Peregoodoff to MAG’s Board of Directors effective January 1, 2024.
  • “We are thrilled to have Tom join our Board,” said Peter Barnes, Chair of the Board.
  • “We are tremendously grateful for Dan’s leadership and steady-hand since 2005 as a director, and as President & CEO from 2005 to 2013 where he led MAG through transformational change and responsible growth,” said Mr. Barnes.
  • in Geophysics and is currently the President, CEO and a director of Apollo Silver Corporation.

Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101

Retrieved on: 
Monday, December 11, 2023
FRCR, Hospital, Bachelor of Science, SAB, Cancer, St Thomas' Hospital, University, Associate professor, Pancreatic cancer, MB, MRCP, Patient, University of Ulm, Pharmaceutical industry

UXBRIDGE, United Kingdom, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced the formation of a new Scientific Advisory Board comprising leading global experts in the field of clinical oncology. The new SAB will be chaired by Prof. Dr. med. Thomas Seufferlein, Director, Department of Gastroenterology, University of Ulm, Germany, and will complement the experience of Immodulon’s new management team to support the advancement of IMM-101 into a pivotal trial for pancreatic cancer as well as broader pipeline progress.

Key Points: 
  • UXBRIDGE, United Kingdom, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced the formation of a new Scientific Advisory Board comprising leading global experts in the field of clinical oncology.
  • The new SAB will be chaired by Prof. Dr. med.
  • My fellow SAB members and I are looking forward to supporting the Immodulon team in their efforts to develop IMM-101 into an effective treatment for patients with metastatic pancreatic cancer,” said Prof. Dr. Thomas Seufferlein, Chair of Immodulon’s Scientific Advisory Board.
  • Thomas Seufferlein (Chairman), University of Ulm, Ulm, Germany
    Dr. Andrew Gaya, BSc, MB SC, MRCP, FRCR, MD, Guy's and St Thomas' Hospital, London, UK